Home › Therapeutic areas › Dermatology › Hidradenitis Suppurativa
Hidradenitis Suppurativa (8 companies)
Companies with an active program in Hidradenitis Suppurativa.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| CRVS | Corvus Pharmaceuticals | DermatologyOncology+1 Rare | 1 | Phase 3 | $889M | 7 |
| KYMR | Kymera Therapeutics | DermatologyImmunology+1 Rare | 1 | Phase 2 | $11.2B | 5 |
| GLUE | Monte Rosa Therapeutics | CardiovascularDermatology+3 Rare | 1 | Phase 2 | $903M | 7 |
| MLTX | MoonLake Immunotherapeutics | DermatologyImmunology Rare | 1 | NDA Submitted | $981M | 4 |
| ORKA | Oruka Therapeutics | DermatologyImmunology Rare | 1 | Phase 2 | $6.81B | 7 |
| SYRE | Spyre Therapeutics | DermatologyImmunology Rare | 1 | Phase 2 | $9.86B | 10 |
| TTRX | Turn Therapeutics | DermatologyInfectious Disease Rare | 1 | Phase 2 | $282M | 4 |
| ZURA | Zura Bio | DermatologyImmunology Rare | 1 | Phase 2 | $394M | 5 |
No companies match.